Company Zalicus Inc Nasdaq
Equities
US98887C2044
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Sales per Business
USD in Million | 2014 | Weight | 2015 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +17,425.00% |
Sales per region
USD in Million | 2014 | Weight | 2015 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +17,425.00% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,184,349 | 26,184,349 ( 100.00 %) | 0 | 100.00 % |
Company contact information
EPIRUS Biopharmaceuticals, Inc.
699 Boylston Street 8th floor
02116, Boston
+617-600-3497
Sector
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- EPRSQ Stock
- Stock
- Company Zalicus Inc